---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-337986"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2026-08-06T20:09:11+00:00"
generated_at: "2026-08-06T20:12:09.583281+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artiva Q2 net loss $25M; cash $349.4M; RMAT granted; Phase 3 RA trial to start H2 2026

## Summary
- Cash, cash equivalents and investments of $349.4M as of June 30, 2026, expected to fund operations into 2029.
- Net loss of $25.0M for Q2 2026 vs $21.3M for Q2 2025; R&D expenses $21.9M vs $17.9M.
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory RA.
- Phase 3 randomized controlled trial of AlloNK plus rituximab vs rituximab alone in ~150 RA patients to start H2 2026.
- Completed ~$300M underwritten offering in May 2026; appointed Diego Miralles, M.D., as president and head of R&D.

## SEC filing metadata
- accession: 0001193125-26-337986
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2026-08-06T20:09:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/0001193125-26-337986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/artv-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-337986
- JSON: https://secwatch.observer/filing/0001193125-26-337986.json
- Plain text: https://secwatch.observer/filing/0001193125-26-337986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.